Zhitong Finance App News, Jianfeng Group (600668.SH) issued an announcement. Recently, Zhejiang Jianfeng Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Drug Registration Certificate” for injectable tedizolamide phosphate approved and issued by the State Drug Administration. Tedizolamide phosphate is suitable for the treatment of acute bacterial skin and skin soft tissue infections (ABSSSI) caused by sensitive isolates of the following gram-positive bacteria: Staphylococcus aureus (including isolates of methicillin-resistant Staphylococcus aureus [MRSA] and methicillin-sensitive Staphylococcus aureus [MSSA]), Streptococcus pyogenes, streptococcus angina (including streptococcus angina, intermediate streptococcus, and streptococcus constellation) and enterococcus faecalis.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.